- Home
- GTBP vs ENVB Comparison
GTBP vs ENVB Comparison
Compare GTBP & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- ENVB
- Stock Information
- Founded
- GTBP 1965
- ENVB 1994
- Country
- GTBP United States
- ENVB United States
- Employees
- GTBP N/A
- ENVB N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- ENVB Health Care
- Exchange
- GTBP Nasdaq
- ENVB Nasdaq
- Market Cap
- GTBP 2.6M
- ENVB 3.0M
- IPO Year
- GTBP N/A
- ENVB N/A
- Fundamental
- Price
- GTBP $0.65
- ENVB $7.04
- Analyst Decision
- GTBP Strong Buy
- ENVB Strong Buy
- Analyst Count
- GTBP 1
- ENVB 1
- Target Price
- GTBP $11.00
- ENVB $10.00
- AVG Volume (30 Days)
- GTBP 4.5M
- ENVB 61.5K
- Earning Date
- GTBP 11-13-2025
- ENVB 11-13-2025
- Dividend Yield
- GTBP N/A
- ENVB N/A
- EPS Growth
- GTBP N/A
- ENVB N/A
- EPS
- GTBP N/A
- ENVB N/A
- Revenue
- GTBP N/A
- ENVB N/A
- Revenue This Year
- GTBP N/A
- ENVB N/A
- Revenue Next Year
- GTBP N/A
- ENVB N/A
- P/E Ratio
- GTBP N/A
- ENVB N/A
- Revenue Growth
- GTBP N/A
- ENVB N/A
- 52 Week Low
- GTBP $0.55
- ENVB $6.63
- 52 Week High
- GTBP $4.10
- ENVB $99.00
- Technical
- Relative Strength Index (RSI)
- GTBP 42.50
- ENVB 94.07
- Support Level
- GTBP $0.65
- ENVB $0.59
- Resistance Level
- GTBP $0.78
- ENVB $7.51
- Average True Range (ATR)
- GTBP 0.06
- ENVB 0.13
- MACD
- GTBP 0.01
- ENVB 0.65
- Stochastic Oscillator
- GTBP 4.82
- ENVB 93.23
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.